CRISPR Activation Enables Functional Analysis of Splice-Altering Variants in Accessible Cells

Study Background and Research Question

Accurate functional characterization of genetic variants that alter mRNA splicing is critical for diagnosing hereditary disorders, especially rare neurogenetic conditions. Many causative variants exert their effects by disrupting canonical or cryptic splice sites, yet predicting the impact of these variants in silico remains unreliable. Traditional RNA diagnostics rely on sampling tissues where the gene of interest is endogenously expressed, but one in five Mendelian disease genes are not transcribed in easily accessible cell types like blood or skin fibroblasts. This presents a major obstacle for streamlined transcriptome-based diagnostics in the clinical laboratory setting (Terkelsen et al., 2024).

Key Innovation from the Reference Study

The central innovation of Terkelsen et al. is the development and validation of a CRISPR activation (CRISPRa) platform to upregulate disease-relevant genes in skin fibroblasts, enabling direct analysis of splice-altering variants in these otherwise non-expressing cells. By using a nuclease-deficient Cas9 (dCas9) fused to the potent tripartite transcriptional activator VPR, and delivering this construct as mRNA, the authors could selectively induce transcription of target genes. This approach bypasses the tissue-specific expression barrier, allowing functional assessment of variants in their native genetic context without the need for invasive sampling of neural or other inaccessible tissues.

Methods and Experimental Design Insights

The CRISPRa workflow designed by Terkelsen et al. involved several critical steps:

• Guide RNAs (sgRNAs) were engineered to target the ~300bp promoter-proximal region upstream of each gene's transcription start site (TSS).
• Skin fibroblast cultures from individuals with suspected monogenic disorders were transfected with mRNA encoding dCas9-VPR and the corresponding sgRNAs.
• After overnight incubation, induction of transcription for the targeted gene (either MPZ or SPAST) was confirmed.
• Splicing patterns were characterized using reverse transcription PCR (RT-PCR), next-generation sequencing (NGS), and long-read sequencing to distinguish transcript isoforms and identify aberrant splicing events arising from patient-specific variants.

The authors' use of mRNA-based delivery for dCas9-VPR is notable, as it minimizes risks of genomic integration and allows precise temporal control—features that are increasingly relevant for diagnostic and therapeutic applications. Furthermore, the protocol is compatible with standard laboratory equipment, supporting rapid adoption in diagnostic settings.

Core Findings and Why They Matter

Applying this CRISPRa platform, the study showed robust induction of the myelin protein zero (MPZ) gene—normally exclusive to Schwann cells of peripheral nerves—and the spastin (SPAST) gene—primarily expressed in the central nervous system—in skin fibroblast cultures. This upregulation enabled clear detection of splicing patterns, including aberrant transcripts associated with pathogenic variants. By activating transcription in a cell type that is easy to obtain from patients, the method allows for direct, context-relevant analysis of spliceogenic variants without requiring samples from affected tissues such as nerve biopsies.

This ex vivo splicing assay provides "proof of principle" for a genetic diagnostic tool that overcomes the tissue specificity bottleneck in RNA diagnostics. Importantly, it supports the reclassification of variants of uncertain significance (VUS) in clinical genomics by offering direct functional evidence—a critical unmet need in rare disease diagnosis (Terkelsen et al., 2024).

Comparison with Existing Internal Articles on Modified Nucleosides in mRNA Research

Although the primary focus of Terkelsen et al. is the application of CRISPRa for variant characterization, their workflow leverages advances in mRNA delivery and translation efficiency, which are also central topics in recent internal literature. For example, reviews such as "N1-Methylpseudouridine: Enhanced mRNA Translation & Reduced Immunogenicity" and "N1-Methylpseudouridine: Driving mRNA Translation Enhancement" highlight how incorporating modified nucleosides like N1-Methylpseudouridine can improve mRNA stability, translation, and reduce innate immune activation in mammalian systems.

These reviews detail how N1-Methylpseudouridine, a chemically modified nucleoside, suppresses eIF2α phosphorylation-mediated translation inhibition and enhances ribosome engagement, resulting in higher protein yield and reduced cytotoxicity in various mammalian cell lines. This is directly relevant to the CRISPRa workflow, where efficient translation of delivered mRNA constructs (such as dCas9-VPR mRNA) is critical for robust gene activation and functional readouts. For researchers seeking to optimize similar workflows, leveraging such modified nucleosides can further support reproducibility and sensitivity in splicing assays and downstream protein expression studies.

Limitations and Transferability

While the CRISPRa-based method represents a significant advance, several limitations merit attention. First, the assay's success depends on efficient delivery and expression of both dCas9-VPR and sgRNAs, which may vary between fibroblast cultures or patient samples. The approach currently focuses on upregulating a single target gene per experiment, which may limit throughput in highly multiplexed diagnostic contexts. Additionally, while the method effectively models splicing in fibroblasts, it may not fully recapitulate tissue-specific splicing regulators present in the nervous system or other specialized tissues, potentially affecting the accuracy of some variant interpretations.

Transferability to other cell types or genes will require empirical validation, especially for targets with tightly regulated or highly restricted expression patterns. Nonetheless, the technique is readily adaptable, and the use of mRNA for delivery aligns well with advances in mRNA modification for protein expression—including protocols utilizing N1-Methylpseudouridine to enhance translation and decrease immunogenicity, as extensively reviewed in the internal literature above.

Protocol Parameters

• sgRNA design: Target the 300-bp region upstream of the transcription start site for optimal CRISPRa efficacy (Terkelsen et al., 2024).
• mRNA delivery: Use mRNA-encoded dCas9-VPR for transient activation; adjust transfection reagent and dosage based on fibroblast line.
• Incubation period: Overnight (typically 16–24 hours) incubation post-transfection is sufficient for measurable gene activation in fibroblast cultures.
• Splicing analysis: Employ RT-PCR and sequencing (short- and long-read) to profile transcript isoforms and identify aberrant splicing events.
• Optional mRNA modification: For enhanced translation and reduced immunogenicity of mRNA constructs, consider incorporating modified nucleosides such as N1-Methylpseudouridine as per established mRNA research benchmarks.

Research Support Resources

For laboratories implementing mRNA-based CRISPRa or similar workflows, the choice of mRNA modification can significantly impact translation efficiency and minimize innate immune responses. Incorporation of N1-Methylpseudouridine (SKU B8340) into synthetic mRNA—such as dCas9-VPR mRNA—has been shown to enhance expression, reduce immunogenicity, and support reliable experimental outcomes in mammalian cell models. According to the product information, this modified nucleoside is validated across a range of cell lines and can be readily integrated into ex vivo diagnostic or research protocols. For further optimization strategies and troubleshooting, researchers may consult detailed internal reviews on mRNA translation enhancement and reduced immunogenicity in mRNA workflows.